[A19-50] Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Last updated 16.09.2019
Commission awarded on 11.06.2019 by the Federal Joint Committee (G-BA).
Adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide
Due to negative effects in several side effects hint of lesser benefit than bortezomib and dexamethasone alone
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|Pomalidomide (multiple myeloma) - Addendum to Commission A19-50
|Pomalidomide - Benefit assessment according to §35a Social Code Book V
|Pomalidomide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment))